4/8/2013

Entegrion and Kedrion Melville agreed to collaborate in the development and commercialization of the former's freeze-dried human plasma Resusix, a shelf-stable alternative to fresh-frozen plasma. The partners plan to initiate clinical studies this year. Kedrion will invest in Entegrion under the agreement.

Related Summaries